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A B S T R A C T
Background: In 2008, the UK introduced an HPV immunisation programme in girls. Population-based
prevalence estimates of bivalent (HPV-16/18), quadrivalent (HPV-6/11/16/18) and 9-valent (HPV-6/11/16/
18/31/33/45/52/58) vaccine types, and comparison over time, are needed to monitor impact, evaluate
eﬀectiveness and guide decision-making on vaccination strategies.
Methods: The third National Survey of Sexual Attitudes and Lifestyles (Natsal-3) in 2010-12, tested urine for
HPV from 2569 sexually-experienced women aged 16–44. We report type-speciﬁc HPV prevalence and compare
results with 1798 women in Natsal-2 (1999–2001) using age-adjusted prevalence ratios (APR).
Findings: In Natsal-3, 4.2% of women aged 16-44y were positive for HPV‐16/18 and 2.9% for HPV-6/11. In
16–20 year olds, 4.5%, 10.8% and 20.7% had at least one bivalent, quadrivalent or 9-valent vaccine type,
respectively. Three-dose vaccine coverage was 52.0% in women aged 18-20y. In this age group, HPV-16/18
prevalence was lower in Natsal-3 than Natsal-2 (5.8% vs 11.2%; APR=0.48[95%CI: 0.24–0.93]), however,
prevalences of HPV-6/11, HPV-31/33/45 and HPV-52/58 were unchanged. HPV-16/18 prevalence was also
unchanged in women aged 21-44y (APR=0.85[0.61–1.19]).
Interpretation: These probability surveys provide evidence of the impact of the bivalent immunisation
programme. Reductions were speciﬁc to HPV-16/18 and to the age group eligible for vaccination. However,
substantial vaccine-preventable HPV remains.
1. Introduction
Over 99% of cervical cancer is caused by persistent infection with
certain high-risk (HR) types of human papillomavirus (HPV) [1,2]. In
2008, the UK introduced an HPV immunisation programme using the
bivalent vaccine that protects against HPV-16 and HPV-18, which
cause over 70% of cervical cancers [3]. This school-based programme
oﬀers the HPV vaccine to all girls aged 12–13 years. A catch-up
programme was implemented in schools and general practice over the
ﬁrst few years for girls aged up to 18 years. In 2012, the programme
switched to the quadrivalent vaccine, which additionally protects
against HPV-6/11, which cause 90% of genital warts [4]. Clinical trials
have shown very high vaccine eﬃcacy against the two high-risk types
included in both vaccines [5,6] as well as some evidence for cross-
protection against HPV-31 for both vaccines and HPV-33 and HPV-45
for the bivalent vaccine [7,8]. More recently, phase III trials have
demonstrated the eﬃcacy of a new 9-valent vaccine, which, in addition
to the types in the quadrivalent vaccine, directly protects against HPV
types 31/33/45/52/58 [9], responsible for a further 20% of cervical
cancers [10].
Population-based prevalence estimates of bivalent, quadrivalent
and 9-valent vaccine types, and comparison over time, are needed to
monitor impact and guide decision-making on vaccination strategies. It
is likely that the cost-eﬀectiveness of using the 9-valent vaccine will be
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considered by the Joint Committee on Vaccination and Immunisation
(JCVI) in the UK and other policy-making bodies internationally. The
National Surveys of Sexual Attitudes and Lifestyles (Natsal) are large
probability sample surveys of the British population that include
demographic and behavioural information linked to STI test results.
Results from Natsal-2, using data collected in 1999–2000, provided
baseline population estimates of type-speciﬁc HPV (from urine sam-
ples) in women aged 18–44 years prior to the introduction of the
bivalent immunisation programme [11]. Using data from Natsal-3,
conducted a decade later using the same methodology, we have
previously reported age-speciﬁc prevalences of HR-HPV [12]. We have
also shown a reduction in HPV-16/18 in women aged 18–20 years
following the introduction of the immunisation programme [12], with
vaccine coverage of 62% in those eligible for the catch-up campaign
[13].
In this paper, we extend the analysis of Natsal-3 data to include
estimates of a wide range of HPV types, including HPV-6/11, HPV-31/
33/45 and HPV-52/58. In addition, more detailed comparison of
results from the two surveys is used to evaluate bivalent vaccine
eﬀectiveness. These include eﬀects on HPV-16/18 prevalence and
non-vaccine types in the age groups targeted by the catch-up campaign,
as well as examining changes in sexual behaviour in the decade
between the surveys.
2. Material and methods
2.1. Participants and procedure
Natsal-3 was a probability sample survey of 15,162 men and
women (8869 women) aged 16–74 years and resident in Britain.
Interviews were carried out during 2010–2012. Participants were
interviewed using computer-assisted personal interviewing, with com-
puter-assisted self-interview for the more sensitive questions. Women
eligible for the national HPV immunisation programme (those born on
or after 1 September 1990, up to 21 years by the end of the interview
period) were asked “Have you ever been vaccinated against cervical
cancer (received HPV vaccine)?”. Further methodological details have
been described elsewhere [14,15]. The Natsal-3 ﬁeldwork dates, and
the age of participants (youngest age 16) meant that some of the
participants were eligible for vaccination, the vast majority of whom
would have been vaccinated as part of the catch-up programme.
At the end of the interview, a sample of participants aged 16–44
years who reported at least one lifetime sexual partner were invited to
provide a urine sample to be tested for STIs, including HPV, and 60%
agreed (similar agreement in men and women) [12]. Written consent
was provided for testing without return of results [16]. Details of the
urine collection, processing and testing procedures have been de-
scribed previously [12,14]. Samples were collected using the
FirstBurst urine collection device [17] and were tested for HPV using
an in-house Luminex-based genotyping assay [18]. HPV types were
classiﬁed as high-risk using the IARC Monograph Working Group
classiﬁcation [19].
The previous Natsal survey (Natsal-2) was carried out in 1999–
2001 [20] and interviewed 11,161 men and women (6399 women)
aged 16–44 years. Sample selection and procedures were similar to
Natsal-3. Urine samples were requested from a sample of 18–44 year
olds, of whom 71% agreed to provide a sample [21] with HPV results
available for 1851 women [11]. Samples were collected using a urine
collection cup. HPV testing protocols for Natsal-2 samples were
identical to those used for Natsal-3.
2.2. Statistical analysis
Data were analysed using Stata (v13.1), accounting for the strati-
ﬁcation, clustering and weighting of the sample. To account for
diﬀerences in the probability of selection for and response to providing
a urine sample, an additional weight, derived from a logistic regression
model, was applied to the urine data for analysis, as described
previously [12,14].
We report prevalence (and 95% conﬁdence intervals (CIs)) of key
HPV type combinations and HPV types in women by age group (16–20,
21–24 and 25–44). Data for comparison between Natsal-2 and Natsal-
3 were available for women aged 18–44. We compare prevalence of
HPV-16/18, HPV-31/33/45, HPV-52/58 and HPV-6/11 in the age
group eligible for vaccination (aged 18–20 years) and the prevalence of
HPV-16/18 in older women (aged 21–44 years). We present age-
adjusted prevalence ratios (APR), calculated using generalised linear
models with a log link function, for the association between survey and
these key type combinations.
Changes in sexual behaviour in men and women aged 18–44, in the
decade between Natsal-2 and Natsal-3, have been previously reported
in detail [15]. To explore whether changes in HPV prevalence could be
due to changes in sexual behaviour, we compared a number of markers
of sexual behaviour in Natsal-2 and Natsal-3, in sexually-experienced
women aged 18–20 years, the age group eligible for vaccination.
2.3. Ethics
Natsal-3 was granted ethical approval by the Oxfordshire Research
Ethics Committee A (Reference: 09/H0604/27). Natsal-2 obtained
ethical approval from University College Hospital, North Thames
Multicentre, and all local research ethics committees in Britain.
3. Results
3.1. Prevalence of HPV types
In Natsal-3, HPV results were available for 2569 sexually-experi-
enced women aged 16–44 years. The prevalence of HPV types and type
combinations, stratiﬁed by age, is shown in Table 1. For all types, the
prevalence was higher in the younger women (aged 16–20 and 21–24
years) than in those aged 25 or over.
In total, 4.2% of 16–44 year olds were positive for bivalent vaccine
types (HPV-16/18) (Table 2). Prevalence was 4.5% in 16–20 year olds
and 7.4% in 21–24 year olds. Vaccine coverage with three doses in
these age groups was 57.2% (52.1–62.1) and 5.6% (3.5–8.7), respec-
tively. HPV-16 was the most common type overall (prevalence of
3.5%), but not in 16–20 year olds. Although the prevalence of HPV-6/
11 was only 2.9% overall, there was a strong association with younger
age (prevalence in those aged 16–20 was 7.0%).
Prevalence of other HR-HPV types found in the 9-valent vaccine
was high – 6.8% overall (Table 1). Table 2 shows that one in eight
women aged 16–44 and one in ﬁve women aged < 25 years, were
positive for at least one 9-valent vaccine type. In 16–20 year olds, 4.5%,
10.8% and 20.7% had at least one bivalent, quadrivalent or 9-valent
vaccine type, respectively.
3.2. Markers of early vaccine eﬀectiveness
Table 3 shows the prevalence of key combinations of HPV types in
women aged 18–20 years in Natsal-2 and Natsal-3 in women. In this
age group, in Natsal-3, 52.0% (46.1–57.9) of women reported having
received all three doses of the HPV vaccine, with an additional 6.0%
(3.6–9.8) reporting having received one or two doses.
In women aged 18–20 years, the prevalence of HPV-16/18 was
lower in Natsal-3 than Natsal-2 (5.8% vs. 11.2%; APR=0.48 (0.24–
0.93)), whereas for older women (aged 21–44 years, Fig. 1), no
signiﬁcant diﬀerence in HPV-16/18 prevalence was seen between the
two surveys. In Natsal-3, the prevalence of HPV-16/18 was lower in
women aged 18–20 years who had been vaccinated compared to
unvaccinated women (OR 0.39 (95%CI 0.17–0.91) p=0.030; AOR
(adjusted for age and number of lifetime partners) 0.46 (95% CI
C. Tanton et al. Papillomavirus Research 3 (2017) 36–41
37
0.20–1.05) p=0.065).
In the women aged 18–20 years, the prevalence of any one or more
of the HR-HPV types found in the 9-valent vaccine (31/33/45/52/58)
was similar in the two surveys, as was the prevalence of HPV-6/11.
There was also no evidence for a diﬀerence in HPV-31/33/45
prevalence between Natsal-2 and Natsal-3.
3.3. Changes in sexual behaviour
Between Natsal-2 and Natsal-3, the proportion of sexually-experi-
enced 18–20 year old women reporting ﬁrst heterosexual intercourse
before the age of 16 increased from 29.2% (24.5–34.4) to 38.8% (34.5–
43.3) (p=0.005). However, there was little evidence for a change in
other markers of risky sexual behaviour. For example, the number of
women reporting ≥5 lifetime partners remained unchanged (39.7%
(33.8–46.0) vs. 43.6% (38.9–48.3) (p=0.332)) as did the number
reporting ≥1 new partner in the past year (55.0% (49.1–60.8) vs
57.7% (53.2–62.0), p=0.483).
4. Discussion
Population-based HPV prevalence estimates, and comparison of
prevalence over time, are needed to inform decisions about future
policy for HPV vaccination in the UK. This paper presents prevalence
estimates for a range of HPV types circulating in the British population
in 2010–2012, and shows that there remains a signiﬁcant amount of
Table 1
Type-specific prevalence of HPV in women aged 16–44 years.
16–20 years 21–24 years 25–44 years All
% 95%CI % 95%CI % 95%CI % 95%CI
Denominator (unwt., wt) 493, 279 464, 294 1612, 1616 2569, 2189
HPV type combinations
High-risk typesa 26.7% [22.6–31.2] 25.0% [21.0–29.5] 12.4% [10.7–14.3] 15.9% [14.4–17.5]
Types 31/33/45 5.6% [3.6–8.7] 6.4% [4.4–9.3] 2.2% [1.6–3.0] 3.2% [2.6–3.9]
Types 31/33/45/52/58 12.7% [9.7–16.4] 10.8% [8.1–14.2] 5.0% [4.0–6.2] 6.8% [5.8–7.8]
Types 6/11 7.0% [4.9–9.8] 5.1% [3.1–8.4] 1.8% [1.3–2.6] 2.9% [2.3–3.7]
HPV types
HPV-6 2.7% [1.4–5.1] 3.1% [1.5–6.5] 0.6% [0.3–1.1] 1.2% [0.8–1.8]
HPV-11 5.1% [3.3–7.7] 2.0% [1.1–3.6] 1.5% [1.0–2.2] 2.0% [1.5–2.6]
HPV-16 3.5% [2.3–5.4] 5.8% [3.9–8.4] 3.0% [2.2–4.1] 3.5% [2.8–4.3]
HPV-18 1.0% [0.5–2.2] 1.6% [0.8–3.5] 0.6% [0.3–1.1] 0.8% [0.5–1.2]
HPV-26 0.6% [0.2–1.8] 0.1% [ < 0.1–1.0] 0.4% [0.2–0.9] 0.4% [0.2–0.8]
HPV-31 1.7% [0.6–4.6] 2.1% [1.1–3.9] 0.7% [0.4–1.1] 1.0% [0.7–1.5]
HPV-33 1.7% [0.7–4.1] 1.2% [0.5–2.6] 0.3% [0.1–0.8] 0.6% [0.4–1.0]
HPV-39 4.7% [3.0–7.3] 2.7% [1.5–4.9] 0.9% [0.6–1.4] 1.6% [1.2–2.2]
HPV-45 3.4% [2.0–5.8] 4.0% [2.4–6.7] 1.4% [1.0–2.1] 2.0% [1.6–2.6]
HPV-51 3.4% [2.1–5.4] 2.3% [1.3–4.0] 1.3% [0.8–2.1] 1.7% [1.2–2.3]
HPV-52 5.4% [3.7–7.9] 2.8% [1.5–5.2] 1.8% [1.2–2.7] 2.4% [1.9–3.1]
HPV-53 4.8% [3.1–7.3] 5.6% [3.7–8.4] 2.2% [1.4–3.2] 2.9% [2.3–3.8]
HPV-56 4.9% [3.3–7.3] 3.6% [2.1–6.2] 1.0% [0.6–1.7] 1.8% [1.4–2.5]
HPV-58 3.2% [2.0–5.2] 2.8% [1.5–5.2] 1.3% [0.8–2.0] 1.7% [1.2–2.3]
HPV-59 3.1% [1.8–5.3] 2.2% [1.2–4.2] 0.8% [0.5–1.3] 1.3% [0.9–1.7]
HPV-66 1.8% [0.9–3.5] 1.2% [0.5–2.8] 1.2% [0.7–2.1] 1.3% [0.9–1.9]
HPV-68 1.7% [0.9–3.3] 2.2% [1.1–4.3] 1.4% [0.8–2.2] 1.5% [1.0–2.2]
HPV-70 0.7% [0.3–1.6] 1.4% [0.7–2.7] 1.2% [0.8–1.8] 1.1% [0.8–1.6]
HPV-73 3.0% [1.9–4.9] 1.7% [0.7–4.0] 0.7% [0.4–1.2] 1.1% [0.8–1.6]
HPV-82 0.5% [ < 0.1–2.2] < 0.1% [ < 0.1–0.7] < 0.1% [ < 0.1–0.5] 0.1% [ < 0.1–0.4]
a Deﬁned as Group 1 (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) & Group 2 A (68) HPV types [19].
Table 2
Prevalence of HPV vaccine types in women aged 16–44 years.
16–20 years 21–24 years 25–44 years All
% 95%CI % 95%CI % 95%CI % 95%CI
Denominator (unwt., wt) 493, 279 464, 294 1612, 1616 2569, 2189
Vaccine HPV types
Bivalent types (HPV-16/18)a 4.5% [3.0–6.6] 7.4% [5.3–10.3] 3.6% [2.7–4.8] 4.2% [3.4–5.2]
Quadrivalent types (HPV-6/11/16/18) 10.8% [8.3–14.0] 12.2% [9.2–16.1] 5.3% [4.3–6.7] 7.0% [6.0–8.1]
9-valent types 20.7% [17.0–24.9] 20.6% [16.8–25.0] 9.9% [8.4–11.6] 12.7% [11.3–14.2]
a Only one woman was positive for both HPV-16 and HPV-18.
Table 3
Prevalence of HPV among women aged 18–20 years in Natsal-2 and Natsal-3.
Natsal-2 Natsal-3
% 95%CI % 95%CI APR 95%CI
Denominator (unwt.,
wt)
140, 150 331, 199
HPV-16/18 11.2% [6.7–
18.3]
5.8% [3.9–8.6] 0.48 [0.24–
0.93]
HPV-31/33/45/52/
58
12.9% [7.9–
20.3]
14.8% [11.1–
19.6]
1.19 [0.69–
2.05]
HPV-31/33/45 5.0% [2.4–
10.0]
7.2% [4.5–
11.4]
1.50 [0.66–
3.44]
HPV-52/58 9.5% [5.3–
16.3]
8.7% [6.1–
12.3]
0.94 [0.48–
1.80]
HPV-6/11 9.5% [5.0–
17.5]
8.9% [6.1–
12.7]
0.91 [0.44–
1.89]
APR – age-adjusted prevalence ratio for Natsal-3 vs. Natsal-2
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vaccine-preventable HPV. Even amongst 16–20 years who were eligible
for the immunisation programme, 5%, 11% and 21% of women were
infected with at least one of the bivalent, quadrivalent or 9-valent
vaccine types, respectively. The Natsal data do nevertheless provide an
early indication of population-based eﬀectiveness of the bivalent
vaccine in women in the age groups eligible for vaccination, with a
~50% reduction seen in the prevalence of HPV-16/18 in 18–20 year
olds (APR=0.48 comparing Natsal-3 to Natsal-2). This reduction was
speciﬁc to the bivalent vaccine types and to the age group eligible for
the catch-up campaign. A recent meta-analysis showed that, in
countries with female vaccination coverage of at least 50%, HPV-16/
18 has reduced by 68% [22].
The strength of Natsal is that the HPV data are collected together
with detailed information on sexual behaviour. This allows us to
examine the counterfactual – could HPV have reduced in this age
group as a result of reductions in risky sexual behaviour in the decade
between the surveys? We have previously reported that there has been
little change in sexual risk behaviour in those aged 18–44 between the
two surveys [14,15]. In the younger age groups, who would have been
eligible for vaccination, we found that the proportion of women
reporting ﬁrst sex before age 16 had increased, although there was
no change in other key risk behaviours suggesting that the prevalence
of HPV would have remained stable or increased in a scenario without
vaccination. National surveillance data from the UK also suggests that
there has been a reduction in the prevalence of the bivalent vaccine
HPV types in the population [23,24]. As shown in a recent meta-
analysis [22], with longer duration of the programme [22], we may see
a reduction in HPV in older women, in men, and in HPV-31/33/45 due
to cohort eﬀects, herd immunity and cross-protection.
Two other UK studies have considered the population-level impact
of a national HPV vaccination programme on HPV prevalence. One
considered changes in HPV type-speciﬁc prevalence in a high-risk
population of young women in England attending for chlamydia
screening [23]. This study demonstrated a reduction in the HPV
vaccine types following the introduction of the bivalent vaccine from
17.6% pre-vaccination (2008) to 8.5% 2–3 years post-vaccination
(2010-11) and 4.0% 4–5 years post-vaccination (2012-13) in the 16–
18 year old age-group with highest vaccination coverage. In Scotland,
among 20–21 year old women attending for cervical screening, the
prevalence of HPV-16/18 reduced from 28.8% in 2009 to 10.1% in
2013 (3-dose vaccination coverage 72.7%) [24]. Our data show little
evidence of a change in the prevalence of HPV-31/33/45 or HPV-31/
33/45/52/58 among 18–20 year olds (APR=1.50 and 1.19 respec-
tively, comparing Natsal-3 to Natsal-2). Conversely, the Scottish data
showed a reduction in HPV-31/33/45 from 13.0% in 2009 to 6.3% in
2013, despite an increase in prevalence of other HR-HPV types over
this time period. It is also encouraging that a decrease in cervical
abnormalities (CIN2 and CIN3) has been seen in Scotland following the
introduction of the national programme using the bivalent vaccine
[25].
The two Natsal studies are large population-based probability
sample surveys, conducted using similar methods a decade apart,
which provide an opportunity to assess the impact of public health
interventions on a national scale. The combination of obtaining
detailed demographic and behavioural data, linked to biological speci-
mens, provides both subjective (eg reported vaccine coverage) and
objective (eg HPV results) measures of process and outcome. Each of
the Natsal datasets is weighted to account for survey participation and
diﬀerential urine selection probabilities and response [14]. However,
the ﬁndings need to be considered in the context of the potential
limitations. Firstly, we have tested urine samples for type-speciﬁc HPV
infection. Whilst urine samples are generally easier to collect and more
acceptable than genital samples, it is has been shown that urine
specimens have a lower sensitivity to detect HR-HPV and HPV-16/
18 infection compared to genital swabs [18]. This lower sensitivity
suggests that the prevalences reported would be an underestimate of
the true HPV type speciﬁc prevalences in the population. Using urine in
consecutive surveys means that the results can be used to compare
relative changes in type-speciﬁc HPV infection. Secondly, although the
overall sample size for Natsal is large, the study was not powered to
assess prevalence estimates, especially in subgroups, such as by both
age and gender, and for the rarer HPV types, or to make comparisons
between surveys. Despite this, we were able to show signiﬁcant
reductions in HPV-16/18 between the surveys. Finally, the data on
vaccine coverage is based on self-report and may be subject to bias.
Comparison of the proportion of respondents who reported having
been vaccinated (62% in that age group and time period in Natsal-3),
with nationally reported data [24,26–30]), suggests that there is
unlikely to be signiﬁcant misclassiﬁcation.
Whilst we show reductions in the bivalent HPV vaccine types, there
remains a considerable HPV burden in the population. The 9-valent
HPV vaccine has been licensed for use in Europe (3-dose schedule)
[31]. If this vaccine were to be considered for the national vaccination
programme then these data will provide a useful baseline to compare
population-based changes in the HPV prevalence of these types.
However, the types included in the 9-valent vaccine are less common
in cervical disease and invasive cancer than the bivalent vaccine types
[3]. Policy-makers, such as JCVI, need to consider these factors, as part
of a comprehensive comparison of the available vaccines, including
measurement of cost-eﬀectiveness.
These data compare HPV prevalence in the British population
before and after the introduction of a national HPV vaccination
programme and strengthen evidence of a population eﬀect against
the HPV types included in the vaccines. Of note, is that these are the
ﬁrst population-based results in the UK general population, rather than
in speciﬁc groups such as those attending for chlamydia screening [23]
or cervical screening [24,25]. The majority of women eligible to receive
the HPV vaccine in this survey will have been vaccinated as part of the
Fig. 1. Prevalence of HPV-16/18 among women aged 18–20 years and 21–44 years in Natsal-2 and Natsal-3.
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catch-up vaccination programme. Detailed description of vaccine
coverage from Natsal-3, including by age, school year and number of
doses, and analysis of demographic and behavioural factors associated
with not being vaccinated, have been previously reported [13]. Those at
higher risk, based on sexual behaviour, were less likely to be vacci-
nated.
These largely baseline data contribute to the evaluation of the
eﬀectiveness and cost-eﬀectiveness of the current strategy and future
decisions on who should be vaccinated, vaccine choice and schedule.
Future surveys will include a larger proportion of vaccinated women,
vaccinated at a younger age, and should see further reductions in the
HPV vaccine types and allow further consideration of changes in the
closely-related HPV types. Longer-term expectations, given higher
coverage with the quadrivalent vaccine, or the introduction of the 9-
valent vaccine, would be a reduction in cervical cancer precursors,
cervical cancer and genital warts [32].
Funding
The study was supported by grants from the Medical Research
Council [Grant no. G0701757] and the Wellcome Trust [Grant no.
084840], with contributions from the Economic and Social Research
Council and Department of Health. NF is supported by a National
Institute for Health Research Academic Clinical Lectureship. SC was
funded to undertake independent research supported by the National
Institute for Health Research (NIHR Research Methods Programme,
Fellowships and Internships, NIHR-RMFI-2014-05-28). The views
expressed in this publication are those of the author(s) and not
necessarily those of the NHS, the National Institute for Health
Research or the Department of Health. The sponsors had no role in
the study design; in the collection, analysis and interpretation of data;
in the writing of the report; and in the decision to submit the article for
publication.
Conﬂicts of Interest
A.M.J. has been a Governor of the Wellcome Trust since 2011.
Acknowledgements
Natsal-3 is a collaboration between University College London, the
London School of Hygiene & Tropical Medicine, NatCen Social
Research, Public Health England (formerly the Health Protection
Agency), and the University of Manchester. The authors thank the
study participants, the team of interviewers and operations and
computing staﬀ from NatCen Social Research; Chinelo Obi, Rebecca
Howell-Jones, Heather Northend, Krishna Gupta, and Tracey Cairns
(Department of HIV and Sexually Transmitted Infections, Public
Health England) for data linkage, anonymization, and data entry;
laboratory staﬀ for their contributions to development of protocols and
testing: Natasha de Silva, Precious Manyenga, Filomeno Coelho da
Silva and Mohammed-Abbas Fazal (Virus Reference Department,
Public Health England).
References
[1] IARC Working Group. IARC Monographs on the Evaluation of Carcinogenic Risks
to Humans. [100B], Lyon, France, World Health Organisation International Agency
for Research on Cancer, 2012, pp.255–313.
[2] J.M. Walboomers, M.V. Jacobs, M.M. Manos, F.X. Bosch, J.A. Kummer, K.V. Shah,
P.J. Snijders, J. Peto, C.J. Meijer, N. Munoz, Human papillomavirus is a necessary
cause of invasive cervical cancer worldwide, J. Pathol. 189 (1999) 12–19.
[3] D. Mesher, K. Cuschieri, S. Hibbitts, J. Jamison, A. Sargent, K.G. Pollock,
N. Powell, R. Wilson, F. McCall, A. Fiander, K. Soldan, Type-speciﬁc, HPV
prevalence in invasive cervical cancer in the UK prior to national HPV immunisa-
tion programme: baseline for monitoring the eﬀects of immunisation, J. Clin.
Pathol. 68 (2015) 135–140.
[4] C.E. Greer, C.M. Wheeler, M.B. Ladner, K. Beutner, M.Y. Coyne, H. Liang,
A. Langenberg, T.S.B. Yen, R. Ralston, Human papillomavirus (HPV) type
distribution and serological response to HPV type 6 virus-Like particles in patients
with genital warts, J. Clin. Microbiol. 33 (1995) 2058–2063.
[5] L.L. Villa, R.L.R. Costa, C.A. Petta, R.P. Andrade, J. Paavonen, E.O. Iverson, S.-
E. Olsson, J. Hoye, M. Steinwall, G. Riis-johannessen, A. Andersson-Ellstrom,
K. Elfgren, G. Von Kroghl, M. Lehtinen, C. Malm, G.M. Tamms, K. Giacoletti,
L. Lupinacci, R. Railkar, F.J. Taddeo, J. Bryan, M.T. Esser, H.L. Sings, A.J. Saah,
E. Barr, High sustained eﬃcacy of a prophylactic quadrivalent human papilloma-
virus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up,
Br. J. Cancer 95 (2006) 1459–1466.
[6] D.M. Harper, E.L. Franco, C.M. Wheeler, A.B. Moscicki, B. Romanowski,
C.M. Roteli-Martins, D. Jenkins, A. Schuind, S.A. Costa Clemens, G. Dubin,
Sustained eﬃcacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against
human papillomavirus types 16 and 18: follow-up from a randomised control trial,
Lancet 367 (2006) 1247–1255.
[7] C.M. Wheeler, X. Castellsague, S.M. Garland, A. Szarewski, J. Paavonen, P. Naud,
J. Salmeron, S.N. Chow, D. Apter, H. Kitchener, J.C. Teixeira, S.R. Skinner,
S.N. Jaisamrarn, G. Limson, B. Romanowski, F.Y. Aoki, T.F. Schwarz, W.A. Poppe,
F.X. Bosch, D.M. Harper, W. Huh, K. Hardt, T. Zahaf, D. Descamps, F. Struyf,
G. Dubin, M. Lehtinen, Cross-protective eﬃcacy of HPV-16/18 AS04-adjuvanted
vaccine against cervical infection and precancer caused by non-vaccine oncogenic
HPV types: 4-year end-of-study analysis of the randomised, double-blind
PATRICIA trial, Lancet Oncol. (2011) 100–110.
[8] D.R. Brown, S.K. Kjaer, K. Sigurdsson, O.E. Iversen, M. Hernandez-Avila,
C.M. Wheeler, G. Perez, L.A. Koutsky, E.H. Tay, P. Garcia, K.A. Ault, S.M. Garland,
S. Leodolter, S.E. Olsson, G.W. Tang, D.G. Ferris, J. Paavonen, M. Steben,
F.X. Bosch, J. Dillner, E.A. Joura, R.J. Kurman, S. Majewski, N. Munoz,
E.R. Myers, L.L. Villa, F.J. Taddeo, C. Roberts, A. Tadesse, J. Bryan, L.C. Lupinacci,
K.E. Giacoletti, H.L. Sings, M. James, T.M. Hesley, E. Barr, The impact of
quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like
particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in
generally HPV-naive women aged 16-26 years, J. Infect. Dis. 199 (2009) 926–935.
[9] E.A. Joura, A.R. Giuliano, O.E. Iversen, C. Bouchard, C. Mao, J. Mehlsen,
E.D. Moreira Jr., Y. Ngan, L.K. Petersen, E. Lazcano-Ponce, P. Pitisuttithum,
J.A. Restrepo, G. Stuart, L. Woelber, Y.C. Yang, J. Cuzick, S.M. Garland, W. Huh,
S.K. Kjaer, O.M. Bautista, I.S. Chan, J. Chen, R. Gesser, E. Moeller, M. Ritter,
S. Vuocolo, A. Luxembourg, A 9-valent HPV vaccine against infection and
intraepithelial neoplasia in women, N. Engl. J. Med 372 (2015) 711–723.
[10] R. Howell-Jones, A. Bailey, S. Beddows, A. Sargent, N. de Silva, G. Wilson,
J. Anton, T. Nichols, K. Soldan, H. Kitchener, Multi-site study of HPV type-speciﬁc
prevalence in women with cervical cancer, intraepithelial neoplasia and normal
cytology, in England, Br. J. Cancer 103 (2010) 209–216.
[11] A.M. Johnson, C.H. Mercer, S. Beddows, S.N. De, S. Desai, R. Howell-Jones,
C. Carder, P. Sonnenberg, K.A. Fenton, C. Lowndes, K. Soldan, Epidemiology of,
and behavioural risk factors for, sexually transmitted human papillomavirus
infection in men and women in Britain, Sex Transm. Infect. 88 (2012) 212–217.
[12] P. Sonnenberg, S. Clifton, S. Beddows, N. Field, K. Soldan, C. Tanton, C.H. Mercer,
F.C. da Silva, S. Alexander, A.J. Copas, A. Phelps, B. Erens, P. Prah, W. Macdowall,
K. Wellings, C.A. Ison, A.M. Johnson, Prevalence, risk factors, and uptake of
interventions for sexually transmitted infections in Britain: ﬁndings from the
National Surveys of Sexual Attitudes and Lifestyles (Natsal), Lancet 382 (2013)
1795–1806.
[13] C. Tanton, K. Soldan, S. Beddows, C.H. Mercer, J. Waller, N. Field, S. Clifton,
A.J. Copas, K. Panwar, P. Manyenga, S.F. da, K. Wellings, C.A. Ison, A.M. Johnson,
P. Sonnenberg, High-risk human papillomavirus (HPV) infection and cervical
cancer prevention in Britain: evidence of diﬀerential uptake of interventions from a
probability survey, Cancer Epidemiol. Biomark. Prev. 24 (2015) 842–853.
[14] B. Erens, A. Phelps, S. Clifton, C.H. Mercer, C. Tanton, D. Hussey, P. Sonnenberg,
W. Macdowall, N. Field, J. Datta, K. Mitchell, A.J. Copas, K. Wellings,
A.M. Johnson, Methodology of the third British National Survey of Sexual Attitudes
and Lifestyles (Natsal-3), Sex Transm. Infect. 90 (2014) 84–89.
[15] C.H. Mercer, C. Tanton, P. Prah, B. Erens, P. Sonnenberg, S. Clifton, W. Macdowall,
R. Lewis, N. Field, J. Datta, A.J. Copas, A. Phelps, K. Wellings, A.M. Johnson,
Changes in sexual attitudes and lifestyles in Britain through the life course and over
time: ﬁndings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal),
Lancet 382 (2013) 1781–1794.
[16] N. Field, C. Tanton, C.H. Mercer, S. Nicholson, K. Soldan, S. Beddows, C. Ison,
A.M. Johnson, P. Sonnenberg, Testing for sexually transmitted infections in a
population-based sexual health survey: development of an acceptable ethical
approach, J. Med. Ethics 38 (2012) 380–382.
[17] C.A. Wisniewski, J.A. White, C.E. Michel, L. Mahilum-Tapay, J.P. Magbanua,
E.C. Nadala Jr., P.J. Barber, B.T. Goh, H.H. Lee, Optimal method of collection of
ﬁrst-void urine for diagnosis of Chlamydia trachomatis infection in men, J. Clin.
Microbiol. 46 (2008) 1466–1469.
[18] S.L. Bissett, R. Howell-Jones, C. Swift, S.N. De, L. Biscornet, J.V. Parry,
N.A. Saunders, M. Nathan, K. Soldan, A. Szarewski, J. Cuzick, S. Beddows, Human
papillomavirus genotype detection and viral load in paired genital and urine
samples from both females and males, J. Med. Virol. 83 (2011) 1744–1751.
[19] V. Bouvard, R. Baan, K. Straif, Y. GRosse, B. Secretan, F. El Ghissassi,
L. Benbrahim-Tallaa, N. Guha, C. Freeman, L. Galichet, V. Cogliano, A review of
human carcinogens–Part B: biological agents, Lancet Oncol. 10 (2009) 321–322.
[20] A.M. Johnson, A.H. Mercer, B. Erens, A.J. Copas, S. McManus, K. wellings,
K.A. Fenton, C. Korovessis, W. Macdowall, K. Nanchahal, S. Purdon, J. Field,
Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours,
Lancet 358 (2001) 1835–1842.
[21] K.A. Fenton, C. Korovessis, A.M. Johnson, A. McCadden, S. McManus, K. Wellings,
C. Tanton et al. Papillomavirus Research 3 (2017) 36–41
40
C.H. Mercer, C. Carder, A.J. Copas, K. Nanchahal, W. Macdowall, G. Ridgway,
J. Field, B. Erens, Sexual behaviour in Britain: reported sexually transmitted
infections and prevalent genital Chlamydia trachomatis infection, Lancet 358
(2001) 1851–1854.
[22] M. Drolet, E. Benard, M.C. Boily, H. Ali, L. Baandrup, H. Bauer, S. Beddows,
J. Brisson, J.M. Brotherton, T. Cummings, B. Donovan, C.K. Fairley, E.W. Flagg,
A.M. Johnson, J.A. Kahn, K. Kavanagh, S.K. Kjaer, E.V. Kliewer, P. Lemieux-
Mellouki, L. Markowitz, A. Mboup, D. Mesher, L. Niccolai, J. Oliphant,
K.G. Pollock, K. Soldan, P. Sonnenberg, S.N. Tabrizi, C. Tanton, M. Brisson,
Population-level impact and herd eﬀects following human papillomavirus vacci-
nation programmes: a systematic review and meta-analysis, Lancet Infect. Dis.
(2015) 565–580.
[23] D. Mesher, K. Panwar, S.L. Thomas, S. Beddows, K. Soldan, Continuing reductions
in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in
England: an ongoing cross-sectional study, BMJ Open 6 (2016) e009915.
[24] R.L. Cameron, K. Kavanagh, J. Pan, J. Love, K. Cuschieri, C. Robertson, S. Ahmed,
T. Palmer, K.G. Pollock, Human papillomavirus prevalence and herd immunity
after introduction of vaccination program, Scotland, 2009–2013, Emerg. Infect.
Dis. 22 (2016) 56–64.
[25] K.G. Pollock, K. Kavanagh, A. Potts, J. Love, K. Cuschieri, H. Cubie, C. Robertson,
M. Cruickshank, T.J. Palmer, S. Nicoll, M. Donaghy, Reduction of low- and high-
grade cervical abnormalities associated with high uptake of the HPV bivalent
vaccine in Scotland 1, Br. J. Cancer (2014) 1824–1830.
[26] Department of Health and Health Protection Agency. Annual HPV vaccine uptake
in England: 2008/09, 2010. 〈http://webarchive.nationalarchives.gov.uk/
20130107105354/http:/www.dh.gov.uk/en/Publicationsandstatistics/
Publications/PublicationsPolicyAndGuidance/DH_111675〉.
[27] Department of Health and Health Protection Agency. Annual HPV vaccine uptake
in England: 2010/11, 2012. 〈http://webarchive.nationalarchives.gov.uk/
20130107105354/https://www.wp.dh.gov.uk/immunisation/ﬁles/2012/03/
120319_HPV_UptakeReport2010-11-revised_acc.pdf〉.
[28] Department of Health and Health Protection Agency. Annual HPV vaccine uptake
in England: 2011/12, 2012. 〈http://webarchive.nationalarchives.gov.uk/
20130123170526/http://immunisation.dh.gov.uk/ann-hpv-vac-cover-england-
201112/〉.
[29] Public Health England. Annual HPV vaccine coverage in England: 2012/13.
〈https://www.gov.uk/government/uploads/system/uploads/attachment_data/
ﬁle/266190/HPV_AnnualDataTable2012_13_SHA_acc2.pdf.31-8-0013〉.
[30] Public Health England. Human Papillomavirus (HPV) Vaccine Coverage in
England, 2008/09 to 2013/14: A review of the full six years of the three-dose
schedule, 2015. 〈https://www.gov.uk/government/uploads/system/uploads/
attachment_data/ﬁle/412264/HPV_Vaccine_Coverage_in_England_200809_to_
201314.pdf〉.
[31] European Medicines Agency. European public assessment report (EPAR) for
Gardasil 9, 2016. 〈www.ema.europa.eu/ema/index.jsp?Curl=pages/medicines/
human/medicines/003852/human_med_001863.jsp &
mid=WC0b01ac058001d124〉.
[32] S. Hartwig, J. Baldauf, G. Dominiak-Felden, F. Simondon, L. Alemany, S. De
Sanjose, X. Castellsaguq, Estimation of the epidemiological burden of HPV-related
anogenital cancers, precancerous lesions, and genital warts in women and men in
Europe: potential additional beneﬁt of a nine-valent second generation HPV
vaccine compared to ﬁrst generation vaccines, Papillomavirus Res. 1 (2015)
90–100.
C. Tanton et al. Papillomavirus Research 3 (2017) 36–41
41
